NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $2.07 -0.01 (-0.48%) (As of 04:29 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends About Can-Fite BioPharma Stock (NYSE:CANF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$2.03▼$2.2150-Day Range$1.94▼$2.9252-Week Range$1.83▼$4.69Volume87,648 shsAverage Volume67,785 shsMarket Capitalization$7.33 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingStrong Buy Company OverviewCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Can-Fite BioPharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks36th Percentile Overall ScoreCANF MarketRank™: Can-Fite BioPharma scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingCan-Fite BioPharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.29) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CANF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CANF. News and Social Media1.4 / 5News Sentiment-0.44 News SentimentCan-Fite BioPharma has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CANF on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by InstitutionsOnly 21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CANF Stock News HeadlinesCan-Fite BioPharma Advances in Pancreatic Cancer TrialNovember 13 at 5:22 AM | markets.businessinsider.comCan-Fite BioPharma Ltd.: Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialNovember 11 at 9:22 AM | finanznachrichten.de625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 13, 2024 | Crypto Swap Profits (Ad)Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialNovember 11 at 7:00 AM | globenewswire.comCan-Fite BioPharma Secures Australian Patent for Obesity DrugNovember 4, 2024 | markets.businessinsider.comCan-Fite BioPharma announces an update related to IP status of NamodenosonNovember 4, 2024 | markets.businessinsider.comCan-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaNovember 4, 2024 | globenewswire.comCan Fite Biofarma (AMEX:CANF) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $2.20 at the beginning of 2024. Since then, CANF shares have decreased by 4.5% and is now trading at $2.10. View the best growth stocks for 2024 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) announced its quarterly earnings data on Tuesday, November, 30th. The company reported ($1.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The company earned $0.25 million during the quarter. When did Can-Fite BioPharma's stock split? Shares of Can-Fite BioPharma reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE). Company Calendar Last Earnings11/30/2021Today11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+733.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$740,000.00 Price / Sales10.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.23Miscellaneous Outstanding Shares3,540,000Free Float3,512,000Market Cap$7.65 million OptionableNot Optionable Beta1.39 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NYSE:CANF) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.